Key Insights

Highlights

Success Rate

33% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 65/100

Termination Rate

33.3%

6 terminated out of 18 trials

Success Rate

33.3%

-53.2% vs benchmark

Late-Stage Pipeline

17%

3 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed with results

Key Signals

2 with results33% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (4)
P 1 (4)
P 2 (4)
P 3 (3)

Trial Status

Recruiting7
Terminated6
Completed3
Active Not Recruiting1
Unknown1

Trial Success Rate

33.3%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT04659343Recruiting

TDM for Optimized Outcome in Patients With mRCC.

NCT03977571Not ApplicableRecruiting

Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

NCT07292168Phase 1RecruitingPrimary

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

NCT06726421Phase 3Recruiting

Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)

NCT02974738Phase 1Active Not Recruiting

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

NCT06995664Not ApplicableRecruiting

Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management

NCT05548621Recruiting

A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)

NCT03013946Phase 3TerminatedPrimary

Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

NCT03991130Phase 2Terminated

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

NCT06321250Phase 1RecruitingPrimary

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma

NCT03905889Phase 1TerminatedPrimary

A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

NCT03562507Phase 2TerminatedPrimary

Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

NCT06377722Phase 2TerminatedPrimary

Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

NCT05103722Not ApplicableTerminatedPrimary

Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma

NCT06161233Not ApplicableCompletedPrimary

Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy

NCT02432846Phase 2CompletedPrimary

Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

NCT04764487Phase 3UnknownPrimary

A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line

NCT03699579CompletedPrimary

Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC

Showing all 18 trials

Research Network

Activity Timeline